SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
暂无分享,去创建一个
J. Vauthey | S. Kopetz | C. Conrad | D. Maru | J. Cloyd | D. Vicente | Y. Chun | T. Aloia | C. Tzeng | K. Omichi | T. Mizuno | Steven H. Wei | S. Wei | Takashi Mizuno
[1] J. Vauthey,et al. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases , 2017, Annals of surgery.
[2] K. Shaw,et al. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer , 2017, PloS one.
[3] P. Lønning,et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases , 2016, International journal of cancer.
[4] M. Makuuchi,et al. Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. , 2016, Surgery.
[5] G. Troncone,et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases , 2016, Journal of Clinical Pathology.
[6] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[7] J. Vauthey,et al. Meta‐analysis of KRAS mutations and survival after resection of colorectal liver metastases , 2015, The British journal of surgery.
[8] M. Rugge,et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.
[9] R. Pai,et al. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer , 2015, Journal of Clinical Pathology.
[10] J. Hardwick,et al. A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer , 2015, Translational oncology.
[11] M. Ladanyi,et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.
[12] Chang Yu,et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer , 2014, Gut.
[13] S. Lee,et al. Comparative Genomic Analysis of Primary and Synchronous Metastatic Colorectal Cancers , 2014, PloS one.
[14] M. Makuuchi,et al. Discrepancy Between Recurrence-Free Survival and Overall Survival in Patients with Resectable Colorectal Liver Metastases: A Potential Surrogate Endpoint for Time to Surgical Failure , 2014, Annals of Surgical Oncology.
[15] M. Washington,et al. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway , 2014, British Journal of Cancer.
[16] H. Moses,et al. The roles of TGFβ in the tumour microenvironment , 2013, Nature Reviews Cancer.
[17] Steven A. Curley,et al. RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.
[18] Seung-Yong Jeong,et al. Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing , 2013, PloS one.
[19] D. Busam,et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. , 2013, Cancer research.
[20] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[21] P. Dijke,et al. TGF-β signalling and its role in cancer progression and metastasis , 2012, Cancer and Metastasis Reviews.
[22] S. Curley,et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[24] S. Curley,et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.
[25] Steven A Curley,et al. Three Hundred and One Consecutive Extended Right Hepatectomies: Evaluation of Outcome Based on Systematic Liver Volumetry , 2009, Annals of surgery.
[26] M. Choti,et al. Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 1669 Patients , 2009, Annals of surgery.
[27] L. Ellis,et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Shuji Ogino,et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.
[29] J. Vauthey,et al. Perioperative chemotherapy for resectable hepatic metastases , 2008, The Lancet.
[30] P. Tekkis,et al. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.
[31] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[32] Jukka-Pekka Mecklin,et al. SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer , 2005, Clinical Cancer Research.
[33] Evelyne M. Loyer,et al. Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.
[34] H T Lynch,et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations , 2004, Journal of Medical Genetics.
[35] Kenneth Hess,et al. Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.
[36] L H Blumgart,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.
[37] J. Massagué,et al. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways , 1996, Nature.
[38] P. Crespo,et al. Ras-dependent activation of MAP kinase pathway mediated by G-protein βγ subunits , 1994, Nature.
[39] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[40] J. Weitz,et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.